Table 1.
Characteristics of HIV+ subjects enrolled in this study.
| Total sample size (number of individuals) | 75 | ||
| Female:Male ratio | 1:3 | ||
| Age at enrollment (years, median and IQR25–75%) | 30 (24–38) | ||
| Estimated time of infection at enrollment (days, median and IQR25–75%) | 75 (54–113) | ||
| Follow-up of Virologic and Immune Characteristics: | |||
| Baseline (N = 75) | 6-month pi (N = 59) | 12-month pi (N = 46) | |
| VL (RNA copies/mL; median and IQR25–75%) a | 61,045 (12,736–455,417) | 18,951 (4298–62,739) | 16,988 (5695–40,105) |
| Log10VL (mean ± SD) a | 4.6 ± 1 | 4 ± 1 | 4 ±0.89 |
| CD4+ T-cell count (cells/μL, median and IQR25–75%) b | 525 (361–698) | 571 (406–673) | 464 (387–585) |
| CD4/CD8 Ratio (Median and IQR25–75%) | 0.6 (0.32–0.83) | 0.55 (0.34–0.8) | 0.61 (0.39–0.93) |
| CD4+ T-cell decay rate (cells/μL/day; median and IQR25–75%) | −0.62 (−0.31 – −0.03) | ||
| Baseline Immune Activation (%cells, median and IQR25–75%) c: | |||
| %CD4+CD38+ | 24.4 (16–36.2) | ||
| %CD4+HLA-DR+ | 4.6 (1.5–11.01) | ||
| %CD4+CD38+HLA-DR+ | 1.2 (0.47–2.8) | ||
| %CD8+CD38+ | 45.2 (21.3–57.1) | ||
| %CD8+HLA-DR+ | 26.5 (15.2–41) | ||
| %CD8+CD38+HLA-DR+ | 13.8 (6.7–30.6) | ||
a Versant HIV-1 RNA 3.0 assay, Siemens. Lower and upper detection limits are 50 and 500,000 RNA copies/mL, respectively (1.7log10 and 5.7log10); b Flow cytometry double platform, FACSCanto, BD Biosciences; c Immune activation was only evaluated at baseline samples by flow cytometry. IQR25–75: Interquartile range 25–75%. VL: Viral Load. pi: postinfection. SD: Standard deviation. IQR: interquartile range; HLA-DR: Human leukocyte antigen - antigen D Related.